Search

Your search keyword '"Wu, Xiao-yu"' showing total 1,375 results
Start Over Author "Wu, Xiao-yu"
1,375 results on '"Wu, Xiao-yu"'

36. Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase-deficient renal cell carcinoma

Author

Zheng, Liang, Zhu, Zi-Ran, Sneh, Tal, Zhang, Wei-Tuo, Wang, Zao-Yu, Wu, Guang-Yu, He, Wei, Qi, Hong-Gang, Wang, Hang, Wu, Xiao-Yu, Fernandez-Garcia, Jonatan, Abramovich, Ifat, Xu, Yun-Ze, Zhang, Jin, and Gottlieb, Eyal

Subjects
Gene mutations -- Health aspects, Fumarase -- Genetic aspects -- Health aspects -- Physiological aspects, Carcinoma, Renal cell -- Genetic aspects -- Prognosis -- Development and progression, Health care industry
Abstract

Germline or somatic loss-of-function mutations of fumarate hydratase (FH) predispose patients to an aggressive form of renal cell carcinoma (RCC). Since other than tumor resection there is no effective therapy for metastatic FH- deficient RCC, an accurate method for early diagnosis is needed. Although MRI or CT scans are offered, they cannot differentiate FH- deficient tumors from other RCCs. Therefore, finding noninvasive plasma biomarkers suitable for rapid diagnosis, screening, and surveillance would improve clinical outcomes. Taking advantage of the robust metabolic rewiring that occurs in FH- deficient cells, we performed plasma metabolomics analysis and identified 2 tumor-derived metabolites, succinyl-adenosine and succinic-cysteine, as excellent plasma biomarkers for early diagnosis. These 2 molecules reliably reflected the FH mutation status and tumor mass. We further identified the enzymatic cooperativity by which these biomarkers are produced within the tumor microenvironment. Longitudinal monitoring of patients demonstrated that these circulating biomarkers can be used for reporting on treatment efficacy and identifying recurrent or metastatic tumors., Introduction Renal cell carcinoma (RCC) is a remarkably heterogeneous malignancy that originates from renal tubular epithelial cells. It accounted for 2%-3% of cancers and caused more than 200,000 deaths worldwide [...]

Published
2023
Full Text
View/download PDF

37. Covalent Antiviral Agents

Author

Mirzaie, Sako, Abdi, Fatemeh, GhavamiNejad, Amin, Lu, Brian, Wu, Xiao Yu, Crusio, Wim E., Series Editor, Dong, Haidong, Series Editor, Radeke, Heinfried H., Series Editor, Rezaei, Nima, Series Editor, Xiao, Junjie, Series Editor, Liu, Xinyong, editor, Zhan, Peng, editor, Menéndez-Arias, Luis, editor, and Poongavanam, Vasanthanathan, editor

Published
2021
Full Text
View/download PDF

39. Research Progress of Cold Spray and Its Application in Ship and Warship Fields

Author

XU Kang - wei, LUO Xiao - tao, WU Xiao - yu, XIE Shu - feng, HUANG Lei, SU Yao, TIAN Jia - jia

Subjects
cold spray, metallic coatings, component repair, corrosion, ships and warships, Materials of engineering and construction. Mechanics of materials, TA401-492, Technology
Abstract

Cold spray, as a low - temperature solid - state forming technology, has a series of advantages over other deposition methods, such as little heat influence towards substrate, minimized particle oxidation, and high deposition efficiency, and therefore it has been widely used for metallic protective coating fabrication, component repair and additive manufacturing. In this work, the characteristics of cold spray were firstly demonstrated from three aspects including cold spraying system, materials, and process. Next, the research progress of cold spraying technology on powder materials design, coating bonding mechanism, and coating microstructure and performance control in recent years were presented. Then, the application of cold spraying technology in the field of foreign naval ships and warships was described in detail. Finally, the research and application of cold spraying technology in the field of naval ships and warships in China were briefly described, and its future development direction was prospected in order to improve the corrosion protection and maintenance support ability of naval ships and warships equipment in China.

Published
2022
Full Text
View/download PDF

47. An emerging terpolymeric nanoparticle pore former as an internal recrystallization inhibitor of celecoxib in controlled release amorphous solid dispersion beads:Experimental studies and molecular dynamics analysis

Author

Lugtu-Pe, Jamie Anne, Zhang, Xuning, Mirzaie, Sako, Chang, Hao Han R., AL-Mousawi, Nour, Chen, Kuan, Li, Yongqiang, Kane, Anil, Bar-Shalom, Daniel, Wu, Xiao Yu, Lugtu-Pe, Jamie Anne, Zhang, Xuning, Mirzaie, Sako, Chang, Hao Han R., AL-Mousawi, Nour, Chen, Kuan, Li, Yongqiang, Kane, Anil, Bar-Shalom, Daniel, and Wu, Xiao Yu

Abstract

Solid oral controlled release formulations feature numerous clinical advantages for drug candidates with adequate solubility and dissolution rate. However, most new chemical entities exhibit poor water solubility, and hence are exempt from such benefits. Although combining drug amorphization with controlled release formulation is promising to elevate drug solubility, like other supersaturating systems, the problem of drug recrystallization has yet to be resolved, particularly within the dosage form. Here, we explored the potential of an emerging, non-leachable terpolymer nanoparticle (TPN) pore former as an internal recrystallization inhibitor within controlled release amorphous solid dispersion (CRASD) beads comprising a poorly soluble drug (celecoxib) reservoir and insoluble polymer (ethylcellulose) membrane. Compared to conventional pore former, polyvinylpyrrolidone (PVP), TPN-containing membranes exhibited superior structural integrity, less crystal formation at the CRASD bead surface, and greater extent of celecoxib release. All-atom molecular dynamics analyses revealed that in the presence of TPN, intra-molecular bonding, crystal formation tendency, diffusion coefficient, and molecular flexibility of celecoxib were reduced, while intermolecular H-bonding was increased as compared to PVP. This work suggests that selection of a pore former that promotes prolonged molecular separation within a nanoporous controlled release membrane structure may serve as an effective strategy to enhance amorphicity preservation inside CRASD.

Published
2024

48. Clinical study of low ⁃ dose rt ⁃ PA combined with transcranial Doppler ultrasonography assisted intravenous thrombolysis

Author

YUAN Chang⁃hong, WU Xiao⁃yu, CHEN Chang⁃chun, WANG Shu⁃pei, LI Xi, JIANG Yan⁃liu, ZHANG Lu, and ZHANG Wei

Subjects
stroke, brain ischemia, tissue plasminogen activator, ultrasonography doppler transcranial, Neurology. Diseases of the nervous system, RC346-429
Abstract

Objective To investigate the efficacy and safety of low dose rt⁃PA combined with transcranial Doppler ultrasonography (TCD) in the intravenous thrombolysis treatment of acute ischemic stroke. Methods A total of 139 patients with acute ischemic stroke admitted to Anhui No. 2 Provincial People's Hospital from July 2016 to May 2019 were randomly divided into the rt⁃PA standard dose group (0.90 mg/kg, total dose≤90 mg), low dose group (0.60 mg/kg, total dose≤60 mg) and low dose combined with TCD group (combined treatment group). TCD was used to continuously monitor the blood flow of middle cerebral artery for 2 h at the beginning of thrombolysis in the combined treatment group. TCD was only performed before and 2 h after thrombolysis in the standard dose group and low dose group. Two hours after thrombolysis, the recanalization rates of intracranial vessels in different treatment groups were compared. National Institutes of Health Stroke Scale (NIHSS) score was used to evaluate the severity of clinical symptoms in each group, and the incidence of symptomatic intracranial hemorrhage 24-48 h after thrombolysis was recorded. The self⁃care ability of 90 d after thrombolytic therapy was evaluated by modified Rankin Scale (mRS), and the mortality rate was calculated. Results The recanalization rate in the combined treatment group were higher than those in the standard dose group (P=0.037) and low dose group (P=0.030), and the NIHSS score 2 h after thrombolysis was lower than that in the standard dose group (P=0.046) and low dose group (P=0.026); the incidence of symptomatic intracranial hemorrhage (P=0.017, 0.024) and 90 d mortality (P=0.005, 0.016) in the low dose group and combined treatment group were lower than those in the standard dose group. Conclusions Low dose rt⁃PA combined with TCD assisted intravenous thrombolysis can improve the recanalization rate without increasing the risk of symptomatic intracranial hemorrhage and death. doi:10.3969/j.issn.1672⁃6731.2021.04.014

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results